What the FDA labels say about taking them together
Ixazomib and rifampin
Ixazomib's FDA label of August 11, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name ixazomib. The ixazomib label: “Avoid concomitant administration of NINLARO with strong CYP3A inducers.”
Check it at the source: the ixazomib FDA label on DailyMed (effective August 11, 2026, Takeda Pharmaceuticals America, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the ixazomib label say about rifampin?
Ixazomib label, drug interactionsAvoid concomitant administration of NINLARO with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St. John's Wort) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (NINLARO), Takeda Pharmaceuticals America, Inc., effective August 11, 2026 (SPL set 038f2461-834b-4488-9ebd-863c83eef5a7), via openFDA; the full label on DailyMed
What does the rifampin label say about ixazomib?
Rifampin's label (effective February 11, 2026) does not name ixazomib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ixazomib | Rifampin | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once